Moderna, Inc. Treasury Stock Acquired, Average Cost Per Share
Moderna, Inc. (MRNA) reported Treasury Stock Acquired, Average Cost Per Share of $0.00 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:TreasuryStockAcquiredAverageCostPerShare · last filed 2026-02-20
- Moderna, Inc. treasury stock acquired, average cost per share for the quarter ending 2023-03-31 was $145.31.
- Moderna, Inc. treasury stock acquired, average cost per share for fiscal 2025 was $0.00.
- Moderna, Inc. treasury stock acquired, average cost per share for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Moderna, Inc. treasury stock acquired, average cost per share for fiscal 2023 was $143.26, a 0.30% increase from fiscal 2022.
- Moderna, Inc. treasury stock acquired, average cost per share for fiscal 2022 was $142.83, a 41.88% decline from fiscal 2021.
| Period end | Treasury Stock Acquired, Average Cost Per Share 3 month | Treasury Stock Acquired, Average Cost Per Share 6 month | Treasury Stock Acquired, Average Cost Per Share 9 month | Treasury Stock Acquired, Average Cost Per Share 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-20 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-20 | |||
| 2023-12-31 | $143.26 10-K · filed 2026-02-20 | |||
| 2023-09-30 | $143.31 10-Q · filed 2023-11-03 | |||
| 2023-06-30 | $143.39 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $145.31 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $142.83 10-K · filed 2025-02-21 | |||
| 2021-12-31 | $245.76 10-K · filed 2024-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |